Blazing the Trail for Amyloidosis in Brazil
Guilherme José Jucá Calheiros carried the Olympic torch in Maceio (AL) Brazil. Guilherme is diagnosed with ATTR Familial Amyloidosis (FAP), which is a rare autosomal dominant amyloidosis disease caused by the deposition of abnormal transthyretin that results from a gene mutation....
Read More
Clinical Trials Update from Ionis Pharmaceuticals
The Phase 3 outcome study of CARDIO-TTR, evaluating patients with TTR amyloid cardiomyopathy through the IONIS-TTRRx program will not be initiated. The other IONIS-TTRRx studies are continuing and include the NEURO-TTR Phase 3 study and Dr. Merrill Benson’s investigator-initiated Phase...
Read More
Phone Interview Research Study for TTR FAP Patients
Phone interview research study for patients diagnosed with Transthyretin Familial Amyloid Polyneuropathy (TTR FAP) to support a new drug development program for treatment of TTR-FAP. The purpose of this phone interview research study is to gather information about the symptoms...
Read More
ARC Launches Clinical Resources App
We are pleased to announce the launch of the ARC's Amyloidosis Clinical Resources App for healthcare professionals.  This new app contains comprehensive disease overviews, diagnostic tools and current treatment protocols for the main types of amyloidosis as well as resources for...
Read More
Advocates Take on The Hill
"By sharing my story, they not only learned about amyloidosis; they also heard about our community's desperate need for approved treatments and pledged their support" I attended Rare Disease Week on Capitol Hill (February 29th– March 4th) as a Rare...
Read More

320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170

ARC is a 501(c)(3) nonprofit organization